慢性乙型肝炎在研抗病拆新药纵览. (Chinese)

An overview of new antiviral drugs under research for chronic hepatitis B. (English)

Chronic hepatitis B caused by hepatitis B virus (HBV) infection remains a major public health problem worldwide, and functional cure and even complete cure of chronic hepatitis B are the goals pursued by drug researchers. At present, widely used nucleos(t) ide analogues and interferon therapy fail to achieve a high cure rate. This article reviews the anti - HBV drugs/therapies under research, including viral entry inhibitors, capsid inhibitors, HBsAg inhibitors, immune modulators, gene editing, and cell therapies, and summarizes related clinical research findings, so as to clarify the latest advances in this field and the new ideas in drug research and development. [ABSTRACT FROM AUTHOR]

HBV 感染引起的漫性Z,型肝炎是全球性的公共卫生问题， 而实现慢性乙型肝炎的功能性治愈甚至完全治愈—直是药物 研发人员追求的目标。 目 前所广泛使用的核昔 （ 酸） 类似物疗法和干扰索疗法的治愈率都不高。 对目前在研的病谔进入抑制剂、衣 壳抑制剂、HBsAg 抑制剂、免疫调节剂以及基因编辑和细胞疗法等多种类型的抗 HBV 药物／疗法进行了综述， 汇总分析了其临床研 究结果， 以明了该领域研究的殿新进展和药物研发的新思路。 [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi is the property of Journal of Clinical Hepatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)